Vivos Therapeutics (VVOS) Capital Expenditures Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -6.52% |
| 10 | Vivos Therapeutics | 5.18 Mn | 3.38 Mn | 2.95 Mn | -46.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.25% |
| Dec 31, 2025 | 2,551.52% |
| Sep 30, 2025 | -143.23% |
| Jun 30, 2025 | 1,185.00% |
| Mar 31, 2025 | -19.21% |
| Dec 31, 2024 | -78.09% |
| Sep 30, 2024 | 144.24% |
| Jun 30, 2024 | -86.18% |
| Mar 31, 2024 | 202.00% |
| Dec 31, 2023 | 276.50% |
| Sep 30, 2023 | -534.00% |
| Jun 30, 2023 | -13.89% |
| Mar 31, 2023 | -58.33% |
| Dec 31, 2022 | -47.64% |
| Sep 30, 2022 | -77.32% |
| Jun 30, 2022 | -61.56% |
| Mar 31, 2022 | -54.20% |
| Dec 31, 2021 | 302.15% |
| Sep 30, 2021 | 3,573.78% |
| Jun 30, 2021 | 16,701.23% |